These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 9609623)

  • 1. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group.
    Lepor H
    Urology; 1998 Jun; 51(6):892-900. PubMed ID: 9609623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group.
    Lepor H
    Urology; 1998 Jun; 51(6):901-6. PubMed ID: 9609624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group.
    Abrams P; Schulman CC; Vaage S
    Br J Urol; 1995 Sep; 76(3):325-36. PubMed ID: 7551841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH.
    Narayan P; Bruskewitz R
    Adv Ther; 2000; 17(6):287-300. PubMed ID: 11317832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia.
    Narayan P; Lepor H
    Urology; 2001 Mar; 57(3):466-70. PubMed ID: 11248621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
    Chapple CR; Wyndaele JJ; Nordling J; Boeminghaus F; Ypma AF; Abrams P
    Eur Urol; 1996; 29(2):155-67. PubMed ID: 8647141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multicentre, open-label study assessing the long-term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
    Schulman CC; Cortvriend J; Jonas U; Lock TM; Vaage S; Speakman MJ
    Eur Urol; 1996; 29(2):145-54. PubMed ID: 8647140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Mac Donald R; Rutks I
    Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia).
    Abrams P; Speakman M; Stott M; Arkell D; Pocock R
    Br J Urol; 1997 Oct; 80(4):587-96. PubMed ID: 9352698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men.
    Kawabe K; Yoshida M; Homma Y;
    BJU Int; 2006 Nov; 98(5):1019-24. PubMed ID: 16945121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tamsulosin for benign prostatic hyperplasia: clinical experience in the primary care setting.
    Flannery MT; Ramsdell J; Ranhosky A; Davidai G; Ruoff G
    Curr Med Res Opin; 2006 Apr; 22(4):721-30. PubMed ID: 16684433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WITHDRAWN: Tamsulosin for benign prostatic hyperplasia.
    Wilt TJ; Macdonald R; Rutks I
    Cochrane Database Syst Rev; 2011 Sep; 2011(9):CD002081. PubMed ID: 21901681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single dose methodology to assess the influence of an alpha1-adrenoceptor antagonist on uroflowmetric parameters in patients with benign prostatic hyperplasia.
    Curtis SP; Eardley I; Boyce M; Larson P; Haesen R; Gottesdiener K; Gertz BJ
    Br J Clin Pharmacol; 2000 Mar; 49(3):269-73. PubMed ID: 10718783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group.
    Narayan P; Tewari A
    J Urol; 1998 Nov; 160(5):1701-6. PubMed ID: 9783935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamsulosin: an update of its role in the management of lower urinary tract symptoms.
    Lyseng-Williamson KA; Jarvis B; Wagstaff AJ
    Drugs; 2002; 62(1):135-67. PubMed ID: 11790159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial.
    Cai JL; Zhou Z; Yang Y; Yan YF; Jing S; Na YQ
    Chin Med J (Engl); 2016 Dec; 129(24):2899-2906. PubMed ID: 27958220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia.
    Kirby RS
    BJU Int; 2003 Jan; 91(1):41-4. PubMed ID: 12614248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Narayan P; Evans CP; Moon T
    J Urol; 2003 Aug; 170(2 Pt 1):498-502. PubMed ID: 12853808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.